Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
暂无分享,去创建一个
A. Stamatoullas | P. Fenaux | L. Adès | N. Vey | Sophie Park | T. Braun | F. Dreyfus | S. Chèze | J. Cahn | D. Bordessoule | G. Étienne | A. Charbonnier | M. Chaury | L. Legros | A. Guerci-Bresler | C. Ravoet | Aline Schmidt | S. Natarajan‐Ame | E. Berger | S. Natarajan‐Amé
[1] F. Mandelli,et al. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. , 2011, Leukemia research.
[2] G. Mufti,et al. Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C , 2010, British journal of haematology.
[3] G. Kroemer,et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia , 2007, Oncogene.
[4] E. Terpos,et al. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. , 2007, Leukemia research.
[5] G. Kroemer,et al. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. , 2007, Oncogene.
[6] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[7] G. Kroemer,et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. , 2006, Blood.
[8] S. Plon,et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro , 2006, Cancer Chemotherapy and Pharmacology.
[9] G. Kroemer,et al. NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome , 2005 .
[10] J. Winter,et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study , 1992, Annals of Hematology.
[11] E. Estey,et al. Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias , 2004, Clinical Cancer Research.
[12] P. Fenaux. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. , 2004, Seminars in hematology.
[13] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[14] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[15] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.